Literature DB >> 10864888

Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.

J Van Rampelbergh1, M G Juarranz, J Perret, A Bondue, R M Solano, C Delporte, P De Neef, P Robberecht, M Waelbroeck.   

Abstract

Vasoactive Intestinal Polypeptide (VIP) interacts with a high affinity to two subclasses of G protein coupled receptors named VPAC(1) and VPAC(2), and has a 3 - 10 fold preference for VPAC(1) over VPAC(2) receptors. Selective ligands for each receptor subclass were recently described. [R(16)]-PACAP (1 - 23) and [L(22)]-VIP are two selective VPAC(1) agonists. Chimaeric human VPAC(2)-VPAC(1) recombinant receptors expressed in CHO cells were used to identify the receptor domains implicated in these two selective ligands recognition. The VPAC(2) preference for [R(16)]-PACAP (1 - 27) over [R(16)]-PACAP (1 - 23) did not require the receptor's NH(2)-terminus domain but involved the whole transmembrane domain. In contrast, the selectivity of [L(22)]-VIP depended only on the presence of the NH(2) terminus and EC(2) domains of the VPAC(1) receptor. The present data support the idea that in the GPCR-B family of receptors the different selective ligands require different domains for their selectivity, and that the peptides carboxyl terminal sequence (amino acids 24 - 27) folds back on the transmembrane receptor domain, close to the peptides, aminoterminus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864888      PMCID: PMC1572139          DOI: 10.1038/sj.bjp.0703384

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

2.  Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.

Authors:  M G Juarranz; J Van Rampelbergh; P Gourlet; P De Neef; J Cnudde; P Robberecht; M Waelbroeck
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

3.  Differential signal transduction by five splice variants of the PACAP receptor.

Authors:  D Spengler; C Waeber; C Pantaloni; F Holsboer; J Bockaert; P H Seeburg; L Journot
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

4.  Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies.

Authors:  M O'Donnell; R J Garippa; N Rinaldi; W M Selig; B Simko; L Renzetti; S A Tannu; M A Wasserman; A Welton; D R Bolin
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

5.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

Authors:  T B Usdin; T I Bonner; E Mezey
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

6.  Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains.

Authors:  A Couvineau; C Rouyer-Fessard; D Darmoul; J J Maoret; I Carrero; E Ogier-Denis; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1994-04-29       Impact factor: 3.575

7.  The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide.

Authors:  E M Lutz; W J Sheward; K M West; J A Morrow; G Fink; A J Harmar
Journal:  FEBS Lett       Date:  1993-11-08       Impact factor: 4.124

8.  Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.

Authors:  P Robberecht; P Gourlet; P De Neef; M C Woussen-Colle; M C Vandermeers-Piret; A Vandermeers; J Christophe
Journal:  Mol Pharmacol       Date:  1992-08       Impact factor: 4.436

9.  Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells.

Authors:  N Inagaki; H Yoshida; M Mizuta; N Mizuno; Y Fujii; T Gonoi; J Miyazaki; S Seino
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

View more
  5 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  The third extracellular loop of the human calcitonin receptor-like receptor is crucial for the activation of adrenomedullin signalling.

Authors:  Kenji Kuwasako; Debbie L Hay; Sayaka Nagata; Tomomi Hikosaka; Kazuo Kitamura; Johji Kato
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.

Authors:  Ingrid Nachtergael; Pascale Vertongen; Ingrid Langer; Jason Perret; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

Review 4.  Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Authors:  Jessica Lu; Sarah J Piper; Peishen Zhao; Laurence J Miller; Denise Wootten; Patrick M Sexton
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

Review 5.  A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.

Authors:  Carmen Martínez; Yasmina Juarranz; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; David Castro; Amalia Lamana; Mario Mellado; Isidoro González-Álvaro; Rosa P Gomariz
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.